Cell Genesys, Inc.

Cell Genesys, Inc. (Nasdaq: CEGE) was a development-stage biotechnology company founded in 1988 and headquartered in South San Francisco, California, with manufacturing operations in Hayward, California and (at one point) Memphis, Tennessee. It was a public company and is no longer independent: BioSante Pharmaceuticals completed a legal merger with Cell Genesys on October 14, 2009, after which "Cell Genesys ceased to exist"; BioSante itself later merged with ANI Pharmaceuticals in 2013. PitchBook lists roughly 61 employees at the time of the 2009 acquisition (deal value about $20.2 million); the company was historically loss-making, reporting a net loss of approximately $93.7 million in fiscal 2004.

Operations. Cell Genesys developed biological therapies for cancer, chiefly two clinical-stage platforms: GVAX cancer immunotherapies (prostate, pancreatic and leukemia trials) and oncolytic virus therapies, notably CG0070 for bladder cancer. Earlier programs covered gene therapy, gene activation and lentiviral vector technology. It monetized non-core assets through spin-outs and licensing — Abgenix (antibody/human monoclonal antibody and transgenic-mouse technology, spun out in 1996 and acquired by Amgen in 2005 for roughly $2.6 billion), Ceregene (2001), the 1997 Somatix acquisition, and a 2007 sale of lentiviral gene-delivery IP to GBP IP/Lentigen for $12 million. This is an operating company, not a non-practicing entity.

Litigation posture. The case data show Cell Genesys as plaintiff in a single tracked suit and as defendant in none — consistent with a one-time commercial/IP dispute rather than a patent-assertion model. That suit, Cell Genesys, Inc. v. GenPharm International, Inc. et al., was a mid-1990s dispute over transgenic mice producing fully human antibodies, filed in California (Santa Clara County Superior Court), not in plaintiff-friendly venues such as the Eastern District of Texas.

Context. Cell Genesys accused GenPharm of misappropriating trade secrets and improperly filing patent applications on the technology; GenPharm counterclaimed and denied the allegations. Cell Genesys dropped the trade-secret action in January 1997. In March 1997, Cell Genesys, Abgenix, Japan Tobacco and Xenotech signed a comprehensive patent cross-license and settlement with GenPharm, resolving all related litigation; Cell Genesys also issued a $15 million convertible note and faced potential milestone payments of up to $30 million to GenPharm.